1887

Abstract

The neutralizing activity of anti-hepatitis C virus (HCV) antibodies is attenuated by a factor present in human sera, which has been proposed to be high-density lipoproteins (HDLs). HDLs have also been shown to facilitate the entry of HCV pseudoparticles (HCVpp) into target cells. Here, the aim of the study was to determine whether HDL-mediated facilitation of HCVpp and infectious HCV (HCVcc) entry and attenuation of neutralization are two related phenomena. The data indicated that HDLs attenuate neutralization at a constant rate. In addition, as for HDL-mediated facilitation of HCVpp entry, attenuation of neutralization depended on the expression of the scavenger receptor BI (SR-BI) and its selective lipid-uptake function. Finally, kinetic experiments showed that HDL-mediated facilitation of HCVpp entry is more rapid than virus neutralization. Altogether, these observations indicate that HCV is exploiting the physiological activity of SR-BI for promoting its entry into target cells, which consequently also protects the virus against neutralizing antibodies.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.81932-0
2006-09-01
2024-12-01
Loading full text...

Full text loading...

/deliver/fulltext/jgv/87/9/2577.html?itemId=/content/journal/jgv/10.1099/vir.0.81932-0&mimeType=html&fmt=ahah

References

  1. Bartosch B., Bukh J., Meunier J.-C., Granier C., Engle R. E., Blackwelder W. C., Emerson S. U., Cosset F.-L., Purcell R. H. 2003a; In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100:14199–14204 [CrossRef]
    [Google Scholar]
  2. Bartosch B., Dubuisson J., Cosset F.-L. 2003b; Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197:633–642 [CrossRef]
    [Google Scholar]
  3. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., Pawlotsky J.-M., Lavillette D., Cosset F.-L. 2005; An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79:8217–8229 [CrossRef]
    [Google Scholar]
  4. Drummer H. E., Maerz A., Poumbourios P. 2003; Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett 546:385–390 [CrossRef]
    [Google Scholar]
  5. Hatch F. T. 1968; Practical methods for plasma lipoprotein analysis. Adv Lipid Res 6:1–68
    [Google Scholar]
  6. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C. M., McKeating J. A. 2003; Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100:7271–7276 [CrossRef]
    [Google Scholar]
  7. Huang Z. H., Gu D., Lange Y., Mazzone T. 2003; Expression of scavenger receptor BI facilitates sterol movement between the plasma membrane and the endoplasmic reticulum in macrophages. Biochemistry 42:3949–3955 [CrossRef]
    [Google Scholar]
  8. Lavillette D., Morice Y., Germanidis G. & 8 other authors 2005a; Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 79:6023–6034 [CrossRef]
    [Google Scholar]
  9. Lavillette D., Tarr A. W., Voisset C. & 7 other authors 2005b; Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265–274 [CrossRef]
    [Google Scholar]
  10. Logvinoff C., Major M. E., Oldach D. & 7 other authors 2004; Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101:10149–10154 [CrossRef]
    [Google Scholar]
  11. Meunier J.-C., Engle R. E., Faulk K. & 7 other authors 2005; Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A 102:4560–4565 [CrossRef]
    [Google Scholar]
  12. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. 1982; Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42:3858–3863
    [Google Scholar]
  13. Nieland T. J. F., Penman M., Dori L., Krieger M., Kirchhausen T. 2002; Discovery of chemical inhibitors of the selective transfer of lipids mediated by the HDL receptor SR-BI. Proc Natl Acad Sci U S A 99:15422–15427 [CrossRef]
    [Google Scholar]
  14. Peng Y., Akmentin W., Connelly M. A., Lund-Katz S., Phillips M. C., Williams D. L. 2004; Scavenger receptor BI (SR-BI) clustered on microvillar extensions suggests that this plasma membrane domain is a way station for cholesterol trafficking between cells and high-density lipoprotein. Mol Biol Cell 15:384–396
    [Google Scholar]
  15. Rhainds D., Brissette L. 2004; The role of scavenger receptor class B type I (SR-BI) in lipid trafficking: defining the rules for lipid traders. Int J Biochem Cell Biol 36:39–77 [CrossRef]
    [Google Scholar]
  16. Rouillé Y., Helle F., Delgrange D. & 10 other authors 2006; Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol 80:2832–2841 [CrossRef]
    [Google Scholar]
  17. Voisset C., Callens N., Blanchard E., Op De Beeck A., Dubuisson J., Vu-Dac N. 2005; High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 280:7793–7799 [CrossRef]
    [Google Scholar]
  18. Wakita T., Pietschmann T., Kato T. & 9 other authors 2005; Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796 [CrossRef]
    [Google Scholar]
  19. Yu M. Y. W., Bartosch B., Zhang P. & 7 other authors 2004; Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 101:7705–7710 [CrossRef]
    [Google Scholar]
/content/journal/jgv/10.1099/vir.0.81932-0
Loading
/content/journal/jgv/10.1099/vir.0.81932-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error